BA
JAZZ icon

Boston Advisors’s Jazz Pharmaceuticals JAZZ Stock Holding History

Boston Advisors’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		$368K Sell
2,870
-24,417
-89% -$3.27M 0.02% 493
2019
Q2 		$3.89M Sell
27,287
-15,392
-36% -$2.07M 0.21% 135
2019
Q1 		$6.1M Buy
42,679
+36,651
+608% +$4.78M 0.31% 89
2018
Q4 		$747K Sell
6,028
-4,795
-44% -$711K 0.04% 385
2018
Q3 		$1.82M Buy
10,823
+2,400
+28% +$413K 0.08% 295
2018
Q2 		$1.45M Buy
8,423
+5,433
+182% +$888K 0.04% 310
2018
Q1 		$451K Sell
2,990
-250
-8% -$36.7K 0.01% 513
2017
Q4 		$436K Sell
3,240
-300
-8% -$41.6K 0.01% 519
2017
Q3 		$518K Hold
3,540
– – 0.01% 488
2017
Q2 		$550K Sell
3,540
-50
-1% -$7.65K 0.01% 468
2017
Q1 		$521K Sell
3,590
-950
-21% -$124K 0.01% 455
2016
Q4 		$495K Sell
4,540
-72,953
-94% -$8.13M 0.01% 481
2016
Q3 		$9.41M Sell
77,493
-83,825
-52% -$11.3M 0.23% 135
2016
Q2 		$22.8M Buy
161,318
+133,038
+470% +$19.6M 0.57% 41
2016
Q1 		$3.69M Buy
28,280
+1,735
+7% +$216K 0.09% 220
2015
Q4 		$3.73M Sell
26,545
-6,650
-20% -$922K 0.09% 228
2015
Q3 		$4.41M Sell
33,195
-10,220
-24% -$1.76M 0.17% 185
2015
Q2 		$7.64M Sell
43,415
-1,195
-3% -$215K 0.32% 101
2015
Q1 		$7.71M Sell
44,610
-660
-1% -$113K 0.3% 106
2014
Q4 		$7.41M Buy
45,270
+8,735
+24% +$1.45M 0.31% 97
2014
Q3 		$5.87M Sell
36,535
-8,175
-18% -$1.26M 0.25% 118
2014
Q2 		$6.57M Buy
44,710
+1,360
+3% +$189K 0.28% 104
2014
Q1 		$6.01M Sell
43,350
-26,071
-38% -$3.92M 0.27% 107
2013
Q4 		$8.79M Sell
69,421
-7,509
-10% -$777K 0.42% 81
2013
Q3 		$7.08M Buy
76,930
+36,340
+90% +$2.93M 0.38% 87
2013
Q2 		$2.79M Buy
+40,590
New +$2.48M 0.13% 138

Other funds holding JAZZ

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $95.5B AUM 28.4% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Boston Advisors's JAZZ Position: Q3 2019 in Review

Boston Advisors reduced its Jazz Pharmaceuticals (JAZZ) stake by 89% in Q3 2019, selling an estimated $3.27M and leaving 2,870 shares worth $368K. The position accounts for 0.02% of the portfolio, ranked #493.

Boston Advisors first reported a position in JAZZ in Q2 2013 and has held it in 26 quarters since. The position peaked at $22.8M in Q2 2016. 406 funds tracked by Wall St. Rank hold JAZZ as of Q3 2019.

  • Boston Advisors held 2,870 shares of Jazz Pharmaceuticals worth $368K as of Q3 2019.
  • Boston Advisors sold 24,417 Jazz Pharmaceuticals shares in Q3 2019, an estimated $3.27M.
  • Jazz Pharmaceuticals made up 0.02% of Boston Advisors's portfolio in Q3 2019, its #493 holding.
  • Boston Advisors first reported a position in Jazz Pharmaceuticals in Q2 2013 and has held it in 26 quarters since.
  • Boston Advisors's Jazz Pharmaceuticals position peaked at $22.8M in Q2 2016.
  • 406 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q3 2019.

Based on Boston Advisors's 13F filing for Q3 2019, filed 5 Nov 2019.